Share This Page
Drug Price Trends for NDC 00641-6194
✉ Email this page to a colleague
Average Pharmacy Cost for 00641-6194
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00641-6194
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PROPOFOL 10MG/ML INJ,EMULSION | Hikma Pharmaceuticals USA Inc. | 00641-6194-10 | 10X20ML | 57.29 | 2021-08-15 - 2026-08-14 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 00641-6194
Introduction
The pharmaceutical landscape continually evolves with the introduction of new medicines, impacting healthcare providers, payers, and pharmaceutical manufacturers. A comprehensive market analysis and price projection for the drug identified by NDC 00641-6194 are fundamental for stakeholders to optimize procurement strategies, pricing negotiations, and lifecycle management. This analysis synthesizes current market conditions, competitive positioning, regulatory factors, and pricing trends, offering an informed outlook for this specific drug.
Drug Profile and Therapeutic Context
NDC 00641-6194 corresponds to [Drug Name], a [drug class or therapeutic category], approved for the treatment of [indication, e.g., metastatic melanoma, rheumatoid arthritis, etc.]. It leverages novel mechanisms or formulations to address unmet patient needs.
Key characteristics include:
- Indications: Approved for use in [list approved indications].
- Formulation & Dosage: Available as [oral/injectable/other], with strengths of [specify dosages].
- Administration: Delivered through [self-injection, infusion, pill].
- Market Authorization: Approved by the FDA in [year], representing an advanced treatment option in its class.
Market Landscape & Competitive Environment
The therapy landscape surrounding NDC 00641-6194 is characterized by:
Market Penetration and Adoption
Since approval, the drug has seen variable uptake driven by factors like clinical efficacy, safety profile, and payer incentives. Early adoption is often concentrated among large academic centers, with broader dissemination linked to formulary inclusion.
Key Competitors
The drug’s competitive positioning depends on current market alternatives, which include:
- Existing biologics: e.g., [Competitor 1], [Competitor 2]
- Small molecule therapies: e.g., [Competitor 3]
- Biosimilars: Emerging biosimilars could influence future pricing and market share.
Current data indicate that NDC 00641-6194 holds a [market share percentage]% in its therapeutic niche, with potential to increase as evidence of comparative efficacy expands.
Regulatory and Policy Factors
Recent policy shifts favoring value-based care, prior authorization, and formulary preference impact the drug's market penetration. Additionally, ongoing patent protections and exclusivity terms are factors delaying generic competition.
Patent status indicates exclusivity until [year], limiting immediate price erosion potential.
Pricing Dynamics and Historical Trends
Pricing benchmarks
Initial wholesale acquisition cost (WAC) for NDC 00641-6194 was set at approximately $[amount] per [dosage unit or course]. This aligns with comparable therapies but reflects its innovative status, unique formulation, and clinical benefits.
Pricing trends
Over the past [period], average prices for similar drugs have demonstrated:
- A [percentage]% increase in list prices annually, driven by R&D recoupment and manufacturing costs.
- Negotiated discounts with payers and pharmacy benefit managers (PBMs), generally reducing net prices by [percentage]%.
Reimbursement landscape
Reimbursement policies significantly influence net revenue. Variability exists across payers, with Medicare Part D and commercial plans applying differing formulary tiers and co-pay structures.
Market Forecast and Price Projections
Short-term outlook (1-2 years)
The initial market reception suggests moderate growth potential, with projected sales reaching $[amount] by 2024, considering current uptake and payer restrictions.
Expected pricing stability is anticipated due to patent protections and limited immediate biosimilar entry. However, negotiations may lead to discounts, with net pricing anticipated to be $[amount] per dose post-rebate adjustments.
Medium to long-term outlook (3-5 years)
Future price trajectories will hinge on:
- Patent expirations: Potential biosimilar entry could trigger price reductions, possibly by [percentage]% or more.
- Regulatory approvals: Expansion into new indications or formulations can sustain or elevate price points.
- Market share growth: As clinical data affirms superior efficacy, increases in utilization could support premium pricing.
Considering these factors, projections estimate a compound annual growth rate (CAGR) of [percentage]% for revenues, with net prices possibly declining to $[amount] as biosimilars or generics penetrate the market.
Impact of Biosimilars and Generics
Given the typical 8-12 year exclusivity period, biosimilar competition will likely emerge after [year], leading to potential price erosion of up to 30-50% depending on competitive intensity.
Price reduction forecasts suggest a decline in the net price from current levels to approximately $[amount] within 5 years post-biosimilar entry.
Market Drivers and Risks
Drivers
- Evidence of superior efficacy or safety.
- Expanding indications and label extensions.
- Favorable formulary positioning.
- Increased adoption in clinical guidelines.
Risks
- Biosimilar competition reducing net prices.
- Payer resistance or restrictive formulary policies.
- Regulatory hurdles or delays.
- Emerging alternative therapies with better cost profiles.
Conclusion
NDC 00641-6194 occupies a niche with promising growth prospects, shaped by regulatory exclusivity, evolving competition, and market dynamics. While initial pricing remains stable, longer-term projections suggest potential price reductions driven by biosimilar entrants and formulary negotiations. Stakeholders should monitor patent expirations, clinical data, and payer policies to optimize positioning.
Key Takeaways
- The current list price of NDC 00641-6194 is approximately $[amount] per dose.
- Market share is growing modestly, with significant upside if new indications or superior efficacy are demonstrated.
- Patent expiration around [year] will likely catalyze biosimilar competition, leading to price reductions of up to 50%.
- Strategic negotiations and formulary inclusion are critical for maintaining favorable pricing.
- Continuous monitoring of regulatory, patent, and clinical developments is essential for accurate forecasting.
FAQs
-
What is the expected timeline for biosimilar entry for NDC 00641-6194?
Biosimilar competitors generally enter the market 8-12 years post-approval; for this drug, that is projected around [year]. -
How does patent expiry impact pricing?
Patent expiry often leads to biosimilar entry, which increases competition and typically results in significant price reductions, impacting revenue potential. -
What factors influence the drug’s pricing negotiations with payers?
Clinical efficacy, safety profile, comparator drug pricing, formulary positioning, and manufacturer rebate strategies are primary factors. -
Are there additional indications that could boost market demand?
Yes, label expansions or new formulations approved for additional indications can expand market reach and justify premium pricing. -
How do healthcare policies impact drug pricing and market share?
Policy shifts towards value-based care, formulary restrictions, and cost-effectiveness assessments influence formulary inclusion and reimbursement levels, affecting overall pricing strategies.
Sources:
[1] [Regulatory filings and approval documents]
[2] [Market research reports]
[3] [Industry pricing trend analyses]
[4] [Patent and exclusivity data]
[5] [Payer and formulary policy updates]
More… ↓
